Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Sartore Bianchi, A ^a   Bencardino, K ^a   Cassingena, A ^a   Venturini, F ^a   Funaioli, C ^a   Cipani, T ^a   Amatu, A ^a   Pietrogiovanna, L ^a   Schiavo, R ^a   Di Nicolantonio, F ^b,c   Artale, S ^a   Bardelli, A ^b,c   Siena, S ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Colorectal cancer; EGFR; KRAS; Monoclonal antibodies

Indexed keywords

2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; AMG 479; ARQ 197; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; BRIVANIB; CETUXIMAB; DALOTUZUMAB; E 7820; EMD 525797; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; IMATINIB; IMC A12; IMO 2055; IRINOTECAN; K RAS PROTEIN; LENALIDOMIDE; MK 0646; MOTESANIB; OXALIPLATIN; PANITUMUMAB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLX 4032; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RESISTANCE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; EXON; GENE MUTATION; HUMAN; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN INTERACTION; SALVAGE THERAPY; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR BIOPSY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE PROTEINS; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; SALVAGE THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649723298     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70012-8     Document Type: Article

References (33)

1. Winer E, Gralow J, Diller L, et al. American Society of Clinical Oncology. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 2008, 27:812-826.
2. Bardelli A, Siena S Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261.
3. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
4. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 8:753-762.
5. Di Nicolantonio F, Martini M, Molinari F, et al. Wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
6. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857.
7. Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, et al. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Target Oncol 2010, 1:19-28.
8. Sridhar SS, Hedley D, Siu LL Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005, 4:677-685.
9. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatchrepair status. Nature 2002, 418:934.
10. Italiano A, Hostein I, Soubeyran I, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 2010, 17:1429-1434.
11. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wildtype metastatic colorectal cancer. Br J Cancer 2009, 18:715-721.
12. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
13. Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010, 28(suppl):15s. Abstr. 3534.
14. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:358-359.
15. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
16. Yarden Y The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl 4):S3-S8.
17. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005, 41:1649-1654.
18. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4:e7287.
19. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009, 101:1308-1324.
20. Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008, 68:1953-1961.
21. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009, 101:465-472.
22. Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009, 15:3184-3188.
23. Zhao L, Vogt PK Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008, 105:2652-2657.
24. Yu CF, Liu ZX, Cantley LG ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase. J Biol Chem 2002, 277:19382-19388.
25. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009, 69:565-572.
26. Reinmuth N, Liu W, Fan F, et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002, 8:3259-3269.
27. Wang Y, Sun Y Insulin-like growth factor receptor-1 as an anti-cancer target: Blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2002, 2:191-207.
28. Chakravarti A, Loeffler JS, Dyson NJ Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62:200-207.
29. Hu YP, Patil SB, Panasiewicz M, et al. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulinlike growth factor receptor and epidermal growth factor receptor. Cancer Res 2008, 68:8004-8013.
30. Reidy DL, Vakiani E, Fakih MG, et al. Randomized, phase II study of the insulinlike growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010 Aug 16.
31. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
32. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009, 10:709-717.
33. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008, 68:8322-8332.